Brise Pharmaceuticals Co., LTD., a China-based company specialising in innovative treatments for chronic pain, announced on Wednesday that it has started the dosing of the initial subjects in its Phase one clinical trial named MBR01T-101.

The trial focuses on the safety and tolerability study of BR01T, a monoclonal antibody designed to target Tropomyosin Receptor Kinase (TrkA) for addressing Chronic Low Back Pain (CLBP).

The MBR01T-101 trial, structured as a randomised, double-blind, and placebo-controlled study, aims to enrol approximately 56 patients with chronic low back pain. The trial is set to be conducted at a JBR CenExel clinical research centre located in Salt Lake City, Utah, USA. The primary objectives of this trial are to assess both the safety and effectiveness of the BR01T treatment in patients with chronic low back pain.